Skip to main navigation Skip to search Skip to main content

Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization

  • Hui K Gan
  • , Martha Lappas
  • , Diana X Cao
  • , Anna Nada Cvrljevic
  • , Andrew M Scott
  • , Terrance Grant Johns

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Abstract Monoclonal antibodies (mAb s) and tyrosine kinase inhibitors targeting the Epidermal Growth Factor receptor (EGFR), which is often pathogenetically (over-)expressed or mutated in epithelial malignancies and glioma, have been modestly successful, with some approved for human use. MAb 806 was raised against de2-7EGFR (or EGFRvIII), a constitutively active mutation expressed in gliomas, but also recognizes a subset (
Original languageEnglish
Pages (from-to)3993 - 4001
Number of pages9
JournalJournal of Cellular and Molecular Medicine
Volume13
Issue number9B
DOIs
Publication statusPublished - 2009

Cite this